ATHA

Athira Pharma, Inc. (ATHA) 10Y Growth Potential Analysis (2026)

Invetso Score: 4.4/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 4.8 (Moderate)

ATHA’s reported growth history is unavailable in the provided metrics, limiting evidence of repeatable revenue compounding versus peers with disclosed multi-year CAGR trends.

Negative ROIC suggests current capital deployment is not yet translating into scalable revenue expansion, unlike stronger peers that reinvest profitably into growth.

Zero capex and R&D intensity imply limited visible internal reinvestment engine, which constrains self-funded expansion relative to peers with heavier growth investment.

The negative cash conversion cycle supports working-capital efficiency, but efficiency alone does not prove durable top-line scaling versus peers with demonstrated growth momentum.

Market Tailwinds

Score:

No segment concentration or market-share data is provided, so ATHA’s exposure to structurally expanding end markets cannot be verified against peers.

The absence of disclosed revenue CAGR metrics weakens evidence that external demand tailwinds are already converting into sustained multi-year growth.

Compared with peers that show measurable organic growth, ATHA’s available data offers little proof of durable demand-driven expansion.

Current leverage is modest, which can support growth funding, but it does not by itself indicate stronger market tailwinds than peers.

Scalability Expansion

Score:

Low net debt provides some balance-sheet flexibility for expansion, but the current return profile suggests scaling has not yet produced attractive compounding.

The lack of R&D and capex intensity indicates a light asset base, which can aid scalability, yet it also signals limited visible growth reinvestment.

Negative ROIC implies incremental capital has not been deployed with peer-leading efficiency, reducing confidence in durable expansion capacity.

Working-capital efficiency is a positive scaling attribute, but peers with proven reinvestment returns still appear better positioned for long-term compounding.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint because it indicates growth capital is not currently generating value, unlike higher-scoring peers.

Missing five-year growth and margin history limits evidence of durable scaling, which weakens confidence in long-term revenue compounding versus peers.

The absence of visible R&D and capex investment may reflect a constrained growth model, reducing the likelihood of sustained expansion.

Without segment data or share trends, ATHA’s ability to defend and extend growth remains less proven than peers with clearer operating disclosure.

Overall Score

Score:

ATHA’s long-term growth capacity appears moderate because balance-sheet flexibility and working-capital efficiency are offset by negative ROIC and limited proof of scalable reinvestment.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Athira Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →